Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids.
Dual-laser flow cytometry, based on the properties of the DNA-binding dyes Hoechst 33342 and propidium iodide, was used, with light and electron microscopy and DNA fragmentation studies, to define the influence of lipoxygenase-derived eicosanoids on apoptosis of human polymorphonuclear neutrophils (PMN) in vitro. Apoptosis was characterized by progression through an early apoptotic phase characterized by condensation of chromatin and coalescence of nuclear lobes, to a late apoptotic phase characterized by nuclear degradation and evanescence, and secondary necrosis. Prolonged exposure of PMN to leukotriene B4 (LTB4) afforded dose-dependent inhibition of constitutive PMN apoptosis (percentage of normal and apoptotic PMN, respectively, after aging for 18 h: vehicle, 30.5 +/- 2.7% and 61.8 +/- 3.2%; LTB4 10(-7) M, 57.6 +/- 1.2% and 37.6 +/- 1.0%) and apoptosis triggered by the classic peptide chemoattractant FMLP. In contrast, apoptosis was not affected by the LTB4 precursor 5(S)-hydroxyeicosatetraenoic acid (HETE), the omega-oxidation LTB4 metabolites 20-hydroxy-LTB4 and 20-carboxy-LTB4, the cysteinyl leukotriene LTC4, the 15-lipoxygenase product 15(S)-HETE, or the lipoxygenase interaction product lipoxin A4. The anti-apoptotic effect of LTB4 was mimicked by 20,20,20-trifluoro-LTB4, LTB4-dimethylamide, and 14,15-dehydro-LTB4, and was blunted by pertussis toxin and genistein, inhibitors of G alpha i GTP-binding proteins and tyrosine kinases, respectively, but not by staurosporine, 15(S)-HETE, or lipoxin A4. This unique pharmacologic profile suggested that LTB4 attenuated apoptosis through activation of cell surface receptors and signaling events distinct from those involved with PMN trafficking, degranulation, and respiratory bursts.
Hébert
M J
MJ
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Takano
T
T
Holthöfer
H
H
Brady
H R
HR
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D002478:Cells, Cultured; D002843:Chromatin / Q000648:ultrastructure; D004247:DNA / Q000032:analysis; D004730:Endothelium, Vascular / Q000166:cytology; D005434:Flow Cytometry; D005456:Fluorescent Dyes; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000494:pharmacology; D007975:Leukotriene B4 / Q000031:analogs & derivatives / Q000494:pharmacology*; D044045:Lipoxins; D008084:Lipoxygenase / Q000378:metabolism*; D009504:Neutrophils / Q000187:drug effects* / Q000648:ultrastructure; D051381:Rats; D018102:Receptors, Leukotriene B4 / Q000187:drug effects / Q000502:physiology; D015398:Signal Transduction
D002843:Chromatin; D005456:Fluorescent Dyes; D006893:Hydroxyeicosatetraenoic Acids; D044045:Lipoxins; D018102:Receptors, Leukotriene B4; C040527:lipoxin A4; D007975:Leukotriene B4; C025984:15-hydroxy-5,8,11,13-eicosatetraenoic acid; D004247:DNA; D008084:Lipoxygenase